A Cost-Effectiveness Analysis of Amivantamab Plus Lazertinib Versus Osimertinib in the Treatment of US and Chinese Patients with EGFR-mutated Advanced Non-Small Cell Lung Cancer.
Lung cancer (Amsterdam, Netherlands)（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined